From Our Partners
Friday, June 24, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Parkinson’s Drug May Help Recovery from Nerve Agent Exposure

by Global Biodefense Staff
September 22, 2014

Research findings recently published in the journal of Neurotoxicology and Teratology show a promising drug candidate to improve recovery from exposure to Soman, an extremely toxic nerve agent that inhibits the cholinesterase enzyme.

Caramiphen, an anticholinergic used in the treatment of Parkinson’s Disease, has antiglutamatergic properties via interactions at the N-methyl-D-aspartate (NMDA) receptor and anticonvulsant effects through the facilitation of gamma-Aminobutyric acid (GABA) inhibition in the basolateral amygdala part of the brain.

These characteristics of Caramiphen reduce seizure duration, body weight loss, motor and cognitive deficits, and brain damage frpm Soman exposure compared to standard therapy alone.

The research was sponsored by the Defense Threat Reduction Agency and conducted by the U.S. Army Medical Research Institute of Chemical Defense (USAMRICD).

The researchers at USAMRICD, managed by DTRA’s Dr. Allen Duplantier, found that caramiphen edisylate administered to rats 30 minutes after seizure onset from Soman exposure worked effectively as an adjunct treatment to the standard therapy of atropine sulfate, oxime (HI-6), and diazepam.

These findings suggest that drug therapies with a combination of anticholinergic, NMDA antagonistic, and GABA enhancing effects might improve the long-term outcome following exposure to a seizure-inducing dose of Soman when added to the post nerve agent exposure regimen used on the battlefield.

Read more at the journal of Neurotoxicology and Teratology: Caramiphen edisylate as adjunct to standard therapy attenuates soman-induced seizures and cognitive deficits in rats.

Source: JSTO in the News, adapted.

From Our Partners
Tags: Antitoxins

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022
Biodefense Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC